Equillium (EQ) Change in Accured Expenses (2018 - 2026)
Equillium (EQ) posted quarterly Change in Accured Expenses of -$257000.0 for Q1 2026, up 67.3% year-over-year from -$153613.7 in Q1 2025, and down 382.42% quarter-over-quarter from $91000.0 in Q4 2025.
Powered by 
Analysis
Equillium (EQ) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Change in Accured Expenses for 9 consecutive years, with -$257000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 67.3% year-over-year to -$257000.0; the TTM figure through Mar 2026 stood at -$1.2 million (up 60.67% YoY), while the FY2025 annual figure was -$1.7 million, up 46.74% from the prior year.
- Change in Accured Expenses slipped to -$257000.0 in Q1 2026 per EQ's latest filing, from $91000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.1 million in Q2 2023 and bottomed at -$1.9 million in Q3 2024.
- Historically, Change in Accured Expenses has averaged -$307529.4 across 5 years, with a median of -$475000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 453.64% — and 2023, when it jumped 1018.34%.
- Equillium's Change in Accured Expenses stood at $908000.0 in 2022, then sank by 288.33% to -$1.7 million in 2023, then climbed by 10.29% to -$1.5 million in 2024, then soared by 105.93% to $91000.0 in 2025, then tumbled by 382.42% to -$257000.0 in 2026.
- Business Quant data shows EQ's Change in Accured Expenses at -$257000.0 in Q1 2026, $91000.0 in Q4 2025, and -$475000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | -352,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -352,000.00 |
| Mar 31, 2026 | -257,000.00 |
| Dec 31, 2025 | 91,000.00 |
| Sep 30, 2025 | -475,000.00 |
| Jun 30, 2025 | -515,000.00 |
| Mar 31, 2025 | -786,000.00 |
| Dec 31, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.86 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | -1.01 Mn |
| Dec 31, 2023 | -1.71 Mn |
| Sep 30, 2023 | 824,000.00 |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | -1.77 Mn |
| Dec 31, 2022 | 908,000.00 |
| Sep 30, 2022 | 971,000.00 |
| Jun 30, 2022 | -229,000.00 |
| Mar 31, 2022 | -1.22 Mn |
| Dec 31, 2021 | 2.03 Mn |
| Sep 30, 2021 | 718,000.00 |